Advances in Gene Editing Technology in Biomedicine
DOI:
https://doi.org/10.61173/1yzv6750Keywords:
Gene editing technology, CRISPR/Cas9, Gene Therapy, Base Editing technology, Transcription regulation toolAbstract
The CRISPR/Cas9 system represents an adaptive immunological defense mechanism observed in bacteria and archaea, which has evolved to protect these organisms from persistent viral and plasmid assaults. This system is comprised of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins. By modifying the simplest type II CRISPR system and introducing a special small guide RNA (sgRNA) and Cas9 endonuclease into the cell, it is possible to cut double-stranded DNA at a specific location and realize knockout or knock-in. CRISPR/Cas9 system has many applications in biological and scientific research fields due to its efficient gene editing function, which makes up for the shortcomings of traditional transgenic technology, such as random integration and genetic instability, and has a broad development prospect. This paper comprehensively discusses the CRISPR/Cas9 technology’s applications in drug discovery and the drug development, such as screening and targeted editing of functional genes, screening and validating drug targets, fabricating animal bioreactors, constructing animal models, and treating genetic diseases, etc. It also discusses the risks and prospects of CRISPR/Cas9 technology.References
[1] Joung, J.K. and J.D. Sander, TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol,
[2013] 14(1): p. 49-55.
[2] Gaj, T., C.A. Gersbach, and C.F. Barbas, 3rd, ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol, 2013. 31(7): p. 397-405.
[3] Maresca, M., et al., Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res,
[2013] 23(3): p. 539-46.
[4] Pauwels, K., et al., Engineering nucleases for gene targeting: safety and regulatory considerations. N Biotechnol, 2014. 31(1): p. 18-27.
[5] Zhang, J., et al., Structure and mechanism of the CMR complex for CRISPR-mediated antiviral immunity. Mol Cell,
[2012] 45(3): p. 303-13.
[6] Wiedenheft, B., S.H. Sternberg, and J.A. Doudna, RNA-guided genetic silencing systems in bacteria and archaea. Nature, 2012. 482(7385): p. 331-8.
[7] Marraffini, L.A. and E.J. Sontheimer, CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science, 2008. 322(5909): p. 1843-5.
[8] Shan, Q., et al., Targeted genome modification of crop plants using a CRISPR-Cas system. Nat Biotechnol, 2013. 31(8): p. Dean&Francis Yuhan Wang 686-8.
[9] Lino, C.A., et al., Delivering CRISPR: a review of the challenges and approaches. Drug Deliv, 2018. 25(1): p. 1234- 1257.
[10] Musunuru, K., The Hope and Hype of CRISPR-Cas9 Genome Editing: A Review. JAMA Cardiol, 2017. 2(8): p. 914- 919.
[11] Branzei, D. and M. Foiani, Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol, 2008. 9(4): p. 297-308.
[12] Lin, S., et al., Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife, 2014. 3: p. e04766.
[13] Grünewald, J., et al., A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing. Nat Biotechnol, 2020. 38(7): p. 861-864.
[14] Gaudelli, N.M., et al., Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature, 2017. 551(7681): p. 464-471.
[15] Landrum, M.J., et al., ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res,
[2016] 44(D1): p. D862-8.
[16] Chu, S.H., et al., Rationally Designed Base Editors for Precise Editing of the Sickle Cell Disease Mutation. Crispr j,
[2021] 4(2): p. 169-177.
[17] Geurts, M.H., et al., CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank. Cell Stem Cell, 2020. 26(4): p. 503-510.e7.
[18] Jin, S., et al., Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. Science, 2019. 364(6437): p. 292-295.
[19] Zuo, E., et al., Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science,
[2019] 364(6437): p. 289-292.
[20] Grunewald, J., et al., Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature,
[2019] 569(7756): p. 433-437.
[21] Zhou, C., et al., Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. Nature, 2019. 571(7764): p. 275-278.
[22] Gao, C., Genome engineering for crop improvement and future agriculture. Cell, 2021. 184(6): p. 1621-1635.
[23] Anzalone, A.V., et al., Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 2019. 576(7785): p. 149-157.
[24] Wang, X., X. Huang, and Y. Liu, Search-and-replace editing of genetic information. Frontiers of Agricultural Science and Engineering, 2020. 7(2).
[25] Li, Y., W. Li, and J. Li, The CRISPR/Cas9 revolution continues: From base editing to prime editing in plant science. J Genet Genomics, 2021. 48(8): p. 661-670.
[26] Sfeir, A. and L.S. Symington, Microhomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway? Trends Biochem Sci, 2015. 40(11): p. 701-714.
[27] Latchman, D.S., Transcription factors: an overview. Int J Biochem Cell Biol, 1997. 29(12): p. 1305-12.
[28] Karin, M., Too many transcription factors: positive and negative interactions. New Biol, 1990. 2(2): p. 126-31.
[29] BUJARD, M.G.H., Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Nati. Acad. Sci. , 1992. 89: p. 5547-5551.
[30] Sadowski, I., et al., GAL4-VP16 is an unusually potent transcriptional activator. Nature, 1988. 335(6190): p. 563-4.
[31] Qi, L.S., et al., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell,
[2013] 152(5): p. 1173-83.
[32] Larson, M.H., et al., CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat Protoc, 2013. 8(11): p. 2180-96.
[33] Gilbert, L.A., et al., CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell, 2013. 154(2): p. 442-51.
[34] Edmondson, D.G., M.M. Smith, and S.Y. Roth, Repression domain of the yeast global repressor Tup1 interacts directly with histones H3 and H4. Genes Dev, 1996. 10(10): p. 1247-59.
[35] Sun, M., et al., The signaling pathways regulated by KRAB zinc-finger proteins in cancer. Biochim Biophys Acta Rev Cancer, 2022. 1877(3): p. 188731.
[36] Kearns, N.A., et al., Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. Development, 2014. 141(1): p. 219-23.
[37] Gao, X., et al., Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. Nucleic Acids Res, 2014. 42(20): p. e155.
[38] Kearns, N.A., et al., Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods, 2015. 12(5): p. 401-403.
[39] Thakore, P.I., et al., Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods, 2015. 12(12): p. 1143-9.
[40] Yeo, N.C., et al., An enhanced CRISPR repressor for targeted mammalian gene regulation. Nat Methods, 2018. 15(8): p. 611- 616.
[41] Farzadfard, F., S.D. Perli, and T.K. Lu, Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas. ACS Synth Biol, 2013. 2(10): p. 604-13.
[42] Xu, X. and L.S. Qi, A CRISPR-dCas Toolbox for Genetic Engineering and Synthetic Biology. J Mol Biol, 2019. 431(1): p. 34-47.
[43] Tanenbaum, M.E., et al., A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell,
[2014] 159(3): p. 635-46.
[44] Koike-Yusa, H., et al., Genome-wide recessive genetic Dean&Francis ISSN 2959-409X screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol, 2014. 32(3): p. 267-73.
[45] Zhou, Y., et al., High-throughput screening of a CRISPR/ Cas9 library for functional genomics in human cells. Nature,
[2014] 509(7501): p. 487-91.
[46] Zhu, S., et al., Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol, 2016. 34(12): p. 1279-1286.
[47] Huang, J., et al., The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2. Molecular and Cellular Biology, 2023. 28(12): p. 4104-4115.
[48] Kasap, C., O. Elemento, and T.M. Kapoor, DrugTargetSeqR: a genomics- and CRISPR-Cas9–based method to analyze drug targets. Nature Chemical Biology, 2014. 10(8): p. 626-628.
[49] Yeung, A.T.Y., et al., Exploiting induced pluripotent stem cell-derived macrophages to unravel host factors influencing Chlamydia trachomatis pathogenesis. Nat Commun, 2017. 8: p. 15013.
[50] Shi, J., et al., Discovery of cancer drug targets by CRISPR- Cas9 screening of protein domains. Nat Biotechnol, 2015. 33(6): p. 661-7.
[51] Li, D., et al., Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol, 2013. 31(8): p. 681-3.
[52] Platt, R.J., et al., CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell, 2014. 159(2): p. 440-55.
[53] Yan, S., et al., A Huntingtin Knockin Pig Model Recapitulates Features of Selective Neurodegeneration in Huntington’s Disease. Cell, 2018. 173(4): p. 989-1002 e13.
[54] Peng, J., et al., Production of Human Albumin in Pigs Through CRISPR/Cas9-Mediated Knockin of Human cDNA into Swine Albumin Locus in the Zygotes. Sci Rep, 2015. 5: p. 16705.
[55] Zeng, F., et al., Production of functional human nerve growth factor from the saliva of transgenic mice by using salivary glands as bioreactors. Sci Rep, 2017. 7: p. 41270.
[56] Zeng, F., et al., Genetically Engineered Pigs as Efficient Salivary Gland Bioreactors for Production of Therapeutically Valuable Human Nerve Growth Factor. Cells, 2022. 11(15).
[57] Niu, Y., et al., Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell, 2014. 156(4): p. 836-43.
[58] Liao, H.K., et al., Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun, 2015. 6: p. 6413.
[59] Bogerd, H.P., et al., Specific induction of endogenous viral restriction factors using CRISPR/Cas-derived transcriptional activators. Proc Natl Acad Sci U S A, 2015. 112(52): p. E7249- 56.
[60] Kaminski, R., et al., Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing. Sci Rep, 2016. 6: p. 22555.
[61] Cheng, H., F. Zhang, and Y. Ding, CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications. Pharmaceutics, 2021. 13(10).
[62] Koo, T., et al., Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression. Nucleic Acids Res, 2017. 45(13): p. 7897-7908.
[63] Cyranoski, D., CRISPR gene-editing tested in a person for the first time. Nature, 2016. 539(7630): p. 479.
[64] Li, L., et al., Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice. ACS Nano, 2017. 11(1): p. 95-111.
[65] Yin, H., et al., Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol,
[2014] 32(6): p. 551-3.
[66] Canver, M.C., et al., BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature, 2015. 527(7577): p. 192-7.
[67] <41422_2019_Article_267.pdf>.
[68] Yeh, W.H., et al., In vivo base editing restores sensory transduction and transiently improves auditory function in a mouse model of recessive deafness. Sci Transl Med, 2020. 12(546).
[69] Pattanayak, V., et al., High-throughput profiling of offtarget DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol, 2013. 31(9): p. 839-43.
[70] Duan, J., et al., Genome-wide identification of CRISPR/Cas9 off-targets in human genome. Cell Res, 2014. 24(8): p. 1009-12.
[71] Chiang, T.W., et al., CRISPR-Cas9(D10A) nickase-based genotypic and phenotypic screening to enhance genome editing. Sci Rep, 2016. 6: p. 24356.
[72] Dang, Y., et al., Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. Genome Biol, 2015. 16: p. 280.
[73] Fu, Y., et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol, 2014. 32(3): p. 279-284.
[74] Slaymaker, I.M., et al., Rationally engineered Cas9 nucleases with improved specificity. Science, 2016. 351(6268): p. 84-8.
[75] Liu, K.I., et al., A chemical-inducible CRISPR-Cas9 system for rapid control of genome editing. Nat Chem Biol, 2016. 12(11): p. 980-987.
[76] Shin, J., et al., Disabling Cas9 by an anti-CRISPR DNA mimic. Sci Adv, 2017. 3(7): p. e1701620.
[77] Jain, S., et al., Precise Regulation of Cas9-Mediated Genome Engineering by Anti-CRISPR-Based Inducible CRISPR Controllers. ACS Synth Biol, 2021. 10(6): p. 1320-1327.
[78] Yin, J., et al., Cas9 exo-endonuclease eliminates chromosomal translocations during genome editing. Nat Commun, 2022. 13(1): p. 1204.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
